BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ: AKRX) today announced that it has added two injectable drug products to its API Supply and Margin Sharing Agreement with Natco Pharma Limited (NSE: NATCOPHARM)(BSE: 524816). One ANDA drug product is indicated for the prevention of nausea and vomiting associated with cancer chemotherapy, while the other ANDA drug product is indicated in the reduction of renal toxicity and xerostomia in cancer patients undergoing chemotherapy and radiation. According to 2006 IMS data, the combined current market size for the two finished products is approximately $433 million. Under the API Supply and Margin Sharing Agreement that was signed May 21, 2007, Natco will be responsible for the supply of the API for both drug products, while Akorn will be responsible for the manufacturing, regulatory submissions, marketing and distribution in the hospital, clinic, and home healthcare markets in the United States and Canada.
